CorMedix screens cheap (~5x EV/EBITDA, ~8x forward P/E) after a 600%+ revenue ramp and a Q1 2026 earnings beat, but the discount is largely deserved: a known CMS reimbursement cliff cuts DefenCath net pricing from July 1, 2026. Base-case fair value ≈ $8.60 vs $7.91 — roughly fairly valued. The genuine optionality is the 2027 CMS post-TDAPA Add-On Adjustment reset (company-estimated 3–5x higher); analyst consensus (~$16.91) treats that recovery as near-certain, this base case does not.
Methodology: EV/EBITDA SOTP. FY2026 adjusted EBITDA guidance midpoint $125M is split ~$88M DefenCath / ~$37M Melinta (estimated allocation). Multiples derive from a peer median ~7.5x EV/EBITDA forward, discounted ~2–2.5x for single-product/single-payer concentration and a defined-but-uncertain 2027 path. The 2027 reset option is sized as ~$55M incremental EBITDA at 4.5x and 50% probability. Operating EV $768M is discounted −12%, then bridged by net debt of −$2M (cash $148M vs $150M convertible notes), divided by 78.4M shares. Probability-weighted FV across scenarios ≈ $8.9, consistent with the $8.60 SOTP base. ⚠️ Not investment advice.
| Component | Assumption | USD/share |
|---|---|---|
| DefenCath franchise | ~$88M FY26E adj. EBITDA × 5.0x EV/EBITDA = $440M EV | +5.61 |
| Melinta anti-infective portfolio | ~$37M FY26E adj. EBITDA × 5.5x EV/EBITDA = $204M EV | +2.60 |
| 2027 post-TDAPA reset option | ~$55M incremental EBITDA × 4.5x × 50% probability = $124M | +1.58 |
| Risk discount | −12% on $768M operating EV (CMS single-payer concentration + convertible dilution overhang) = −$91M | −1.16 |
| Net cash/(debt) bridge | Cash & investments $148M − $150M convertible notes = −$2M | −0.03 |
| FV base case | Sum: 5.61 + 2.60 + 1.58 − 1.16 − 0.03, on 78.4M shares | ≈ $8.60 |
Short interest above 20% of float signals a heavily contested name. The bears' thesis is the H2 2026 reimbursement cliff; the bulls' is the 2027 reset. With 8.66 days to cover, any clearly positive CMS news could force rapid covering — but the elevated level also reflects informed skepticism, not just speculation. No class-action, short-seller report or SEC investigation was identified in the last 12 months; no insider sales above $500K were flagged in available filings.
| Item | FY2024 | FY2025 | Guidance 2026 |
|---|---|---|---|
| Net revenue ($M) | 43.5 | 311.7 | 325–345 |
| Product sales ($M) | 43.5 | 304.3 | ~320 (est.) |
| Adjusted EBITDA ($M) | ~0 (est.) | ~220–240 (synergized PF) | 115–135 |
| Net income ($M) | net loss (N/D) | ~175 (incl. one-time tax benefit) | ~70–85 (est.) |
| Cash & investments ($M) | N/D | ~148 | N/D |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
| Revenue ($M) | 39.1 | 39.7 | 104.3 | ~127.0 | 127.4 |
| Adj. EBITDA ($M) | ~22e | ~21e | ~45e | ~79 | 70.0 |
| Net income ($M) | 20.6 | 19.8 | 108.6* | ~35e | 38.6 |
| Net margin % | 53% | 50% | 104%* | ~28% | 30% |
Business model — CorMedix
DefenCath (dialysis) ~$255–270M FY26E (~77% rev) 🟢 ramping volume Antimicrobial catheter lock solution for hemodialysis CVC patients. Volume still expanding across dialysis organizations, but net pricing falls in H2 2026 with the TDAPA transition. Highest-margin franchise. Melinta acute-care portfolio ~$70–80M FY26E (~22% rev) 🟡 first full year Hospital anti-infectives (Vabomere, Orbactiv, Kimyrsa, Minocin, Rezzayo, plus authorized generics). 2026 is the first full-year contribution; diversifies revenue away from CMS dialysis reimbursement. Pipeline & label expansion minimal FY26E revenue 🟡 to prove DefenCath utilization/label expansion opportunities and the Melinta anti-infective pipeline. Optionality rather than a current earnings driver; execution and additional indications are the watch items.
Legal, regulatory and risk analysis
SWOT analysis
- +First and only FDA-approved antimicrobial catheter lock solution (DefenCath).
- +Explosive commercial ramp — revenue from $43.5M to $311.7M in one year.
- +GAAP-profitable with ~$125M adj. EBITDA guided even in the trough year.
- +Melinta acquisition adds a diversified acute-care portfolio and hospital channel.
- +Roughly net-debt-neutral balance sheet (~$148M cash vs $150M convertible).
- −~77% revenue concentration in a single product and single indication.
- −Revenue economics fully exposed to CMS reimbursement methodology.
- −FY2025 net income flattered by a large one-time deferred-tax benefit.
- −$150M convertible notes create a dilution / leverage overhang.
- −Limited disclosed late-stage pipeline beyond DefenCath and Melinta.
- →2027 post-TDAPA CMS Add-On Adjustment estimated 3–5x H2 2026 — a defined re-rating catalyst.
- →DefenCath utilization and label expansion across more dialysis organizations.
- →Melinta anti-infective pipeline and hospital contract wins.
- →Further M&A-driven diversification funded by operating cash flow.
- !Post-TDAPA pricing decline deeper than modeled.
- !Unfavorable 2027 CMS methodology versus management's estimate.
- !Competition entering the catheter lock solution space.
- !Payer / large-dialysis-organization pushback on pricing.
- !Eventual loss of exclusivity for DefenCath.
Summary by assessment area
- GAAP-profitable; FY26 adj. EBITDA guidance $115–135M even in the trough year.
- ~$148M cash vs $150M convertible notes — net debt roughly neutral, ~1.2x gross leverage.
- Strong cash conversion; FY25 net income flattered by a one-time tax benefit.
- Base FV ≈ $8.60 vs $7.91 — modest +9% upside.
- ~5.0x EV/EBITDA fw, below peer median ~7.5x — discount justified, not an anomaly.
- Consensus ~$16.91 prices a near-certain 2027 recovery this base case does not assume.
- Fairly valued: the cheap multiple compensates for the reimbursement cliff.
- Binary 2027 CMS catalyst dominates the thesis; 21.6% short interest.
- Risk/reward roughly symmetric — not the asymmetric value setup the screen implied.
Sources: CorMedix Q1 2026 8-K / 10-Q (earnings release, May 2026), FY2025 10-K and 8-K, FY2026 guidance 8-K, Melinta acquisition press releases; market and short-interest data from Yahoo Finance, CNN Markets, MarketBeat, Fintel and StockAnalysis. Market data (2026-05-18 close, verified across ≥2 recent sources): CRMD ~$7.91, market cap ~$620M, 52-week range $6.13–$17.43, ~78.4M shares outstanding. Short interest: 21.6% of float (~16.9M shares, 8.66 days to cover). Peer EV/EBITDA forward multiples (COLL, ANIP, HRMY) are estimates; FY2025 adjusted EBITDA $220–240M is the company's fully-synergized pro forma figure; quarterly adjusted-EBITDA values for Q1–Q3 2025 are estimates. This document is for informational purposes only and does not constitute financial or investment advice.